open access

Online first
Editorial
Published online: 2022-06-15
Get Citation

Editorial comment on “Long-term outcomes following drug-eluting balloons versus thin-strut drug-eluting stents for treatment of recurrent restenosis in drug-eluting stents”

Osama Shoeib1, Francesco Burzotta2
DOI: 10.33963/KP.a2022.0146
·
Pubmed: 35703432
Affiliations
  1. Department of Cardiology, Tanta University, Tanta, Egypt
  2. Department of Cardiovascular Sciences, Fondazione Policlinico Universitario A Gemelli IRCCS, Università Cattolica del Sacro Cuore, Rome, Italy

open access

Online first
Editorial
Published online: 2022-06-15

Abstract

Not available

Abstract

Not available
Get Citation
About this article
Title

Editorial comment on “Long-term outcomes following drug-eluting balloons versus thin-strut drug-eluting stents for treatment of recurrent restenosis in drug-eluting stents”

Journal

Kardiologia Polska (Polish Heart Journal)

Issue

Online first

Article type

Editorial

Published online

2022-06-15

Page views

32

Article views/downloads

38

DOI

10.33963/KP.a2022.0146

Pubmed

35703432

Authors

Osama Shoeib
Francesco Burzotta

References (15)
  1. Wolny R, Kowalik I, Januszek R, et al. Long-term outcomes following drug-eluting balloons versus thin-strut drug-eluting stents for treatment of recurrent restenosis in drug-eluting stents. Kardiol Pol. 2022 [Epub ahead of print].
  2. Goel SS, Dilip Gajulapalli R, Athappan G, et al. Management of drug eluting stent in-stent restenosis: A systematic review and meta-analysis. Catheter Cardiovasc Interv. 2016; 87(6): 1080–1091.
  3. Kawamoto H, Ruparelia N, Latib A, et al. Drug-Coated balloons versus second-generation drug-eluting stents for the management of recurrent multimetal-layered in-stent restenosis. JACC Cardiovasc Interv. 2015; 8(12): 1586–1594.
  4. Cassese S, Byrne RA, Tada T, et al. Incidence and predictors of restenosis after coronary stenting in 10 004 patients with surveillance angiography. Heart. 2014; 100(2): 153–159.
  5. Negi SI, Torguson R, Gai J, et al. Intracoronary brachytherapy for recurrent drug-eluting stent failure. JACC Cardiovasc Interv. 2016; 9(12): 1259–1265.
  6. Piraino D, Cimino G, Buccheri D, et al. Recurrent in-stent restenosis, certainty of its origin, uncertainty about treatment. Int J Cardiol. 2017; 230: 91–96.
  7. Windecker S, Kolh P, Alfonso F, et al. 2014 ESC/EACTS Guidelines on myocardial revascularization: The Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS)Developed with the special contribution of the European Association of Percutaneous Cardiovascular Interventions (EAPCI). Eur Heart J. 2014; 35(37): 2541–2619.
  8. Shlofmitz E, Case BC, Chen Y, et al. Waksman in-stent restenosis classification: a mechanism-based approach to the treatment of restenosis. Cardiovasc Revasc Med. 2021; 33: 62–67.
  9. Jeger RV, Eccleshall S, Wan Ahmad WA, et al. Drug-Coated Balloons for Coronary Artery Disease: Third Report of the International DCB Consensus Group. JACC Cardiovasc Interv. 2020; 13(12): 1391–1402.
  10. Alfonso F, García J, Pérez-Vizcayno MJ, et al. New stent implantation for recurrences after stenting for in-stent restenosis: implications of a third metal layer in human coronary arteries. J Am Coll Cardiol. 2009; 54(11): 1036–1038.
  11. Kubo S, Kadota K, Otsuru S, et al. Optimal treatment of recurrent restenosis lesions after drug-eluting stent implantation for in-stent restenosis lesions. EuroIntervention. 2013; 9(7): 788–796.
  12. Clever YP, Cremers B, von Scheidt W, et al. Compassionate use of a paclitaxel coated balloon in patients with refractory recurrent coronary in-stent restenosis. Clin Res Cardiol. 2014; 103(1): 21–27.
  13. Wańha W, Bil J, Januszek R, et al. Long-Term Outcomes Following Drug-Eluting Balloons Versus Thin-Strut Drug-Eluting Stents for Treatment of In-Stent Restenosis (DEB-Dragon-Registry). Circ Cardiovasc Interv. 2021; 14(9): e010868.
  14. Alfonso F, Pérez-Vizcayno MJ, Cárdenas A, et al. A Prospective Randomized Trial of Drug-Eluting Balloons Versus Everolimus-Eluting Stents in Patients With In-Stent Restenosis of Drug-Eluting Stents: The RIBS IV Randomized Clinical Trial. J Am Coll Cardiol. 2015; 66(1): 23–33.
  15. Katsanos K, Spiliopoulos S, Kitrou P, et al. Risk of death following application of paclitaxel-coated balloons and stents in the femoropopliteal artery of the leg: a systematic review and meta-analysis of randomized controlled trials. J Am Heart Assoc. 2018; 7(24): e011245.

Regulations

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By VM Media Sp. z o.o. VM Group Sp.k., ul. Świętokrzyska 73 , 80–180 Gdańsk, Poland

phone:+48 58 320 94 94, fax:+48 58 320 94 60, e-mail: viamedica@viamedica.pl